NRG-GU015

Open to Accrual

Return to Protocol Table

The Phase III Adaptive Radiation And Chemotherapy For Muscle Invasive Bladder Cancer Trial (ARCHER)

Principal Investigator

Scott Delacroix, MD,

Co-Principal Investigator(s)

Himanshu Nagar, MD,

Status

Open to Accrual

Date Opened To Accrual

August 14 2025

Disease Site

Genitourinary [GU]

Bladder

Phase

III

Developmental Therapeutics

Yes

Primary Objective

Demonstrate non-inferiority ofultra-hypofractionated (SBRT) compared to hypofractionated RT with a 10%non-inferiority margin (from 50% to 40%) in the rate of bladder-intactevent-free survival (BI-EFS) at 3 years (corresponding to a hazard ratio<1.32).

Patient Population

Patients with Histologically proven, cT2-T3,N0M0 urothelial carcinoma of the bladder prior to randomization.

Target Accrual

486

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.